Roles of Human elF1 in Translation Preinitiation Complex Assembly

人类 eF1 在翻译前启动复合体组装中的作用

• 批准号: 7331321
• 负责人: RAFAEL E LUNA
• 金额: $ 4.96万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7331321
• 关键词: Address; Binding; Chemicals; Complex; Condition; Development; Elongation Factor; Eukaryotic Initiation Factors; Face; Future; Goals; Grant; Human; In Vitro; Individual; Initiator Codon; Investigation; Label; Laboratories; Lead; Malignant Neoplasms; Maps; Mediating; NMR Spectroscopy; Nuclear Magnetic Resonance; Numbers; Peptide Initiation Factors; Pharmaceutical Preparations; Pharmacologic Substance; Process; Proteins; Research; Research Design; Role; Saccharomyces cerevisiae; Scanning; Staging; Structure; System; Translation Initiation; Translations; Yeasts; base; inhibitor/antagonist; insight; novel; reconstitution; release factor; small molecule

DESCRIPTION (provided by applicant): Based on studies in yeast Saccharomyces cerevisiae, the eukaryotic translation initiation factor (elF) 5 has been shown to serve a critical role in the assembly of an important intermediate in the 43S pre-initiation complex via the formation of multiple binding interfaces mediated by its carboxyl terminal domain (elF5-CTD). This grant proposes investigations to determine the structural mechanisms involved in the formation of the human elF1/elF5-CTD complex, which is an important step in the assembly of the translation pre-initiation complex. Objective/Hypothesis: Preliminary studies in our laboratory indicate that elF1 and elF5-CTD interact and form a complex. Utilizing NMR spectroscopy, we are currently determining the mutual binding interface of the elF1/elF5-CTD complex. This grant proposes investigations to determine the multiple binding-interfaces of the elF1/elF5-CTD complex with components of the human pre-initiation complex. This novel complex mediates an important step in the eukaryotic translation initiation process. In order to investigate the structural role of the elF1/elF5-CTD sub-complex within the pre-initiation complex, we will address the following specific aims: 1.) Map the mutual binding interface of the human elF1/elF5 complex and determine its structure. 2.) Characterize the interaction of human elF5-CTD and elF1/elF5- CTD complex with elF2-beta and elF4G. Study Design: In order to tackle the multiple binding-interface of the elF1/elF5-CTD complex, the scope of this grant will encompass the utilization of nuclear magnetic resonance (NMR) spectroscopy. We will optimize conditions for NMR chemical shift mapping of the multiple binding-interface of the elF1/elF5-CTD complex. An in vitro reconstitution system involving purified proteins in which one component is 15N-labeled (e.g. elF5-CTD) while in the presence of its unlabeled binding partners (e.g. elF1 and elF2-beta). The mapping of the multiple faces of the human elF1/elF5 complex will give an invaluable insight into the assembly the human translation pre-initiation complex. Insights into the structural interactions of the elF1/elF5-CTD sub-complex could lead to the future development of small molecule inhibitors to modulate human translation initiation leading to novel, robust pharmaceutical drugs to treat cancer.

描述（由申请人提供）：基于在酵母酿酒酵母中的研究，已显示真核翻译起始因子（elF）5在43 S前起始复合物中重要中间体的组装中起关键作用，该组装通过其羧基末端结构域（elF 5-CTD）介导的多个结合界面的形成。该补助金建议进行调查，以确定参与形成人类elF 1/elF 5-CTD复合物的结构机制，这是翻译前起始复合物组装的重要步骤。目的/假设：我们实验室的初步研究表明，elF 1和elF 5-CTD相互作用并形成复合物。利用NMR光谱，我们目前正在确定eIF 1/eIF 5-CTD复合物的相互结合界面。该资助提议进行研究以确定elF 1/elF 5-CTD复合物与人类前起始复合物组分的多个结合界面。这种新的复合物介导真核生物翻译起始过程中的重要步骤。为了研究eIF 1/eIF 5-CTD亚复合物在前起始复合物内的结构作用，我们将解决以下具体目标：1.）绘制人eIF 1/eIF 5复合物的相互结合界面并确定其结构。2.）的情况。表征人eIF 5-CTD和eIF 1/eIF 5- CTD复合物与eIF 2-β和eIF 4G的相互作用。研究设计：为了解决elF 1/elF 5-CTD复合物的多重结合界面，该资助的范围将包括利用核磁共振（NMR）光谱。我们将优化eIF 1/eIF 5-CTD复合物的多重结合界面的NMR化学位移映射的条件。涉及纯化蛋白质的体外重建系统，其中一种组分是15 N标记的（例如eIF 5-CTD），同时存在其未标记的结合配偶体（例如eIF 1和eIF 2-β）。人类eIF 1/eIF 5复合物的多个面的映射将为人类翻译前起始复合物的组装提供宝贵的见解。对eIF 1/eIF 5-CTD亚复合物的结构相互作用的了解可能导致未来开发小分子抑制剂来调节人翻译起始，从而产生治疗癌症的新型、稳健的药物。